Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03738826 · ClinicalTrials.gov registry record · NA
Reducing Disparities in Medication Adherence in SLE
A NA study of Systemic Lupus Erythematosus, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 135
- Enrollment target
- 1
- Study location
NCT03738826: Completed NA study of Systemic Lupus Erythematosus, sponsored by Duke University.
NCT03738826 is a NA study of Systemic Lupus Erythematosus that has completed, run by Duke University. The registered enrollment target is 135 participants, below the 379-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03738826, a NA study of Systemic Lupus Erythematosus, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 135 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to assess the feasibility of using Surescripts refill data during the clinical encounter to improve medication adherence in patients with systemic lupus erythematosus
Primary Outcome
Feasibility as measured by documentation of adherence assessment made by provider.
Conditions Studied
Interventions
- BEHAVIORAL Behavioral Intervention
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2019-10-02 |
| Est. Completion | 2020-06-07 |
| Phase | NA |
What the finished NCT03738826 record still lists
NCT03738826 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 379-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which Behavioral Intervention is the first listed.
NCT03738826 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03738826 about?
NCT03738826 is a clinical study titled "Reducing Disparities in Medication Adherence in SLE". This is a pilot study to assess the feasibility of using Surescripts refill data during the clinical encounter to improve medication adherence in patients with systemic lupus erythematosus
What is the current status of trial NCT03738826?
This trial is currently completed. It is a NA study. The enrollment target is 135 participants. The study started on 2019-10-02. Estimated completion is 2020-06-07.
What conditions does trial NCT03738826 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT03738826?
The interventions under investigation include: Behavioral Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT03738826?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03738826 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03738826's enrollment target sits among peer trials
135 50th of 99 higher than 50 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Intervention to Improve Communication and Medication Adherence in Lupus
RECRUITING · NA
-
Peer Approaches to Lupus Self-management
ACTIVE NOT RECRUITING · NA
-
The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB
ACTIVE NOT RECRUITING · NA
-
REACH (Restore Energy, Activity Can Help) Lupus Study
ACTIVE NOT RECRUITING · NA
-
Breaking Implicit Bias Habits: An Individuation Pilot Study In Rheumatology
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI